[HTML][HTML] Hidden treasures in “ancient” microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal …
K Kerkentzes, V Lagani, I Tsamardinos… - Frontiers in …, 2014 - frontiersin.org
Objective: Novel statistical methods and increasingly more accurate gene annotations can
transform “old” biological data into a renewed source of knowledge with potential clinical …
transform “old” biological data into a renewed source of knowledge with potential clinical …
A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus …
F Kong, H Yang, Q Wang, Z Wei, X Ye - European Radiology, 2023 - Springer
Objectives This study aimed to build and validate a prediction model that can predict
progression-free survival (PFS) in patients with advanced non-small cell lung cancer …
progression-free survival (PFS) in patients with advanced non-small cell lung cancer …
Epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta‐analysis
M Ameratunga, N Pavlakis, V Gebski… - Asia‐Pacific Journal …, 2014 - Wiley Online Library
Aim Tyrosine kinase inhibitors (TKI s) targeting the epidermal growth factor receptor (EGFR)
are well established in treating metastatic pulmonary adenocarcinoma, especially patients …
are well established in treating metastatic pulmonary adenocarcinoma, especially patients …
Triggering of suicidal erythrocyte death by gefitinib
A Al Mamun Bhuyan, T Wagner, H Cao… - Cellular Physiology and …, 2017 - karger.com
Abstract Background/Aims: The epidermal growth factor receptor-tyrosine kinase inhibitor
gefitinib is effective against several malignancies and is mainly utilized in the treatment of …
gefitinib is effective against several malignancies and is mainly utilized in the treatment of …
PET/CT in therapy evaluation of patients with lung cancer
NH Langer, TN Christensen, SW Langer… - Expert review of …, 2014 - Taylor & Francis
FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis
and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the …
and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the …
Discovery of novel 2, 4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance …
Abstract A series of novel 2, 4-diarylaminopyrimidine derivatives of AZD9291 were
discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) …
discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) …
Formulating Management Strategies Using Fast-and-Frugal Trees (A Decision Tool to Transform Clinical Practice Guidelines and Clinical Pathways into Decision …
B Djulbegovic, I Hozo - Threshold Decision-making in Clinical Medicine …, 2023 - Springer
Formulating Management Strategies Using Fast-and-Frugal Trees (A Decision Tool to
Transform Clinical Practice Guidelines and Clinical Pathways into Decision Support at the Point …
Transform Clinical Practice Guidelines and Clinical Pathways into Decision Support at the Point …
Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations
YX Bao, XD Zhao, HB Deng, CL Lu, Y Guo, X Lu… - Cellular Oncology, 2016 - Springer
Background Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …
[HTML][HTML] Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status
Y Zheng, W Fang, J Deng, P Zhao, N Xu… - Journal of Thoracic …, 2014 - ncbi.nlm.nih.gov
Background In non-small cell lung cancer (NSCLC), the well-developed epidermal growth
factor receptor (EGFR) is an important therapeutic target. EGFR activating gene mutations …
factor receptor (EGFR) is an important therapeutic target. EGFR activating gene mutations …
ARMS 法检测非小细胞肺癌表皮生长因子受体基因突变及临床意义
徐慧英， 洪炜龙， 谢双双， 潘晓东， 白永恒， 林向阳… - 中国应用生理学 …, 2014 - cqvip.com
目的: 探讨应用突变特异性扩增系统法(ARMS) 检测非小细胞肺癌(NSCLC) 表皮生长因子受体(
EGFR) 基因突变的特点. 方法: 收集220 例浙江南部地区NSCLC 患者肿瘤样本, 分别采用ARMS …
EGFR) 基因突变的特点. 方法: 收集220 例浙江南部地区NSCLC 患者肿瘤样本, 分别采用ARMS …